The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.
Revolution Medicines’ daraxonrasib meaningfully extends the overall survival at a rate that is higher than many frontline chemotherapy regimens achieve. Image credit: [lassedesignen]/Shutterstock.com
At the 2026 American Society of Clinical Oncology (ASCO) annual congress, topline data from the Phase III RASolute 302 was presented at the plenary session.
At an 8.5-month follow-up all primary and secondary endpoints were met. Previously treated metastatic pancreatic cancer patients who received Revolution Medicine’s oral RAS(ON) inhibitor daraxonrasib achieved a median overall survival (OS) of 13.2 months, almost double that of chemotherapy(6.7 months) in the control arm with a hazard ratio of 0.40. The survival benefit was matched by a meaningful improvement in progression-free survival (PFS) of 7.2 months vs 3.6 months. Response rates nearly tripled with an objective response rate (ORR) of 31.6% compared to 11.2% in the chemotherapy arm. The field is ecstatic about the prospect of a targeted therapy meaningfully extending OS at a rate that is higher than many frontline chemotherapy regimens achieve.
